Microbiology and Immunology · 2013 · 59 citations · 30 references
MedicineDermatologyMicrobiologyAntimicrobial PharmacotherapyDermatopathologyMycologyAntifungal AgentsAntifungal PharmacologyAntifungal PharmacotherapyAntifungal ResistanceAntifungal TherapyAntifungal Resistance MechanismsAntifungal Susceptibility TestingAntifungal TreatmentsCausative PathogensDermatophyte TreatmentFractional Inhibitory Concentration IndexFungal DermatosesFungal Skin Diseases
To investigate the antifungal drug susceptibility of fungi responsible for dermatomycoses, minimum inhibition concentration (MIC) tests were performed in 44 strains of dermatophytes, including Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton tonsurans, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum, with six antifungal drugs (amorolfine, terbinafine, butenafine, ketoconazole, itraconazole and bifonazole) by broth microdilution assay according to Clinical Laboratory Standard Institute protocols. Six possible dermatomycosis-causing non-dermatophytic fungi were also tested. The two major causes of tinea, T. rubrum and T. mentagrophytes, showed significantly different sensitivities to ketoconazole and bifonazole. Clinically derived dermatophytes were sensitive to the six antifungal drugs tested. However, non-dermatophytes, especially Fusarium spp., tended to be resistant to these antifungal drugs. In Trichophyton spp., the MICs of non-azole drugs had narrower distributions than those of azoles. To evaluate the effects of antifungal drug combinations, the fractional inhibitory concentration index was calculated for the combination of amorolfine and itraconazole as representative external and internal drugs for dermatophytes. It was found that this combination had synergistic or additive effects on most dermatophytes, and had no antagonistic effects. The variation in susceptibility of clinically derived fungal isolates indicates that identification of causative fungi is indispensable for appropriately choosing effective antifungal drugs in the early stages of infection. The results of combination assay suggest that multiple drugs with different antifungal mechanisms against growth of dermatophytes should be used to treat refractory dermatomycoses, especially onychomycosis.
30
Dominique Sanglard, Karl Kuchler, Françoise Ischer et al. · Antimicrobial Agents and Chemotherapy · 1995 · 817 citations
Antifungal drug resistance in pathogenic fungi.
H. Vanden Bossche, Françoise Dromer, I Improvisi et al. · PubMed · 1998 · 292 citations
Koichi Makimura, Yoshiko Tamura, Takashi Mochizuki et al. · Journal of Clinical Microbiology · 1999 · 248 citations · Full text
Life Sciences, Biology, Microbiology +16
Aditya K. Gupta, Yatika Kohli · British Journal of Dermatology · 2003 · 171 citations
Medicine, Dermatology, Pharmacology +17
Koichi Makimura, Takashi Mochizuki, Atsuhiko Hasegawa et al. · Journal of Clinical Microbiology · 1998 · 156 citations · Full text
Life Sciences, Biology, Microbiology +16